Group 1 - The company is optimistic about its performance in the recent quarter, indicating a broad-based beat and positive momentum heading into 2026 [2] - The guidance for the year is set at 3% to 6% growth, primarily driven by the bioprocessing franchise, which is expected to see high single-digit growth [2] - In the Life Sciences sector, end markets are showing signs of improvement and stabilization, particularly in the pharmaceutical industry [3]